These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

518 related items for PubMed ID: 26980298

  • 1. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ, Chun SM, Kim D, Kwon H, Jang EK, Kim TY, Kim WB, Shong YK, Jang SJ, Song DE, Kim WG.
    Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
    [Abstract] [Full Text] [Related]

  • 2. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
    Latteyer S, Tiedje V, König K, Ting S, Heukamp LC, Meder L, Schmid KW, Führer D, Moeller LC.
    Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
    [Abstract] [Full Text] [Related]

  • 3. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B, Godbert Y, Perot G, Al Ghuzlan A, Bardet S, Belleannée G, Crinière L, Do Cao C, Fouilloux G, Guyetant S, Kelly A, Leboulleux S, Buffet C, Leteurtre E, Michels JJ, Tissier F, Toubert ME, Wassef M, Pinard C, Hostein I, Soubeyran I.
    Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
    [Abstract] [Full Text] [Related]

  • 4. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, Tuttle RM, Sherman E, Gill AJ, Ghossein R.
    Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
    [Abstract] [Full Text] [Related]

  • 5. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 6. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
    Duan H, Li Y, Hu P, Gao J, Ying J, Xu W, Zhao D, Wang Z, Ye J, Lizaso A, He Y, Wu H, Liang Z.
    Histopathology; 2019 Dec 01; 75(6):890-899. PubMed ID: 31230400
    [Abstract] [Full Text] [Related]

  • 7. Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing.
    Sykorova V, Dvorakova S, Vcelak J, Vaclavikova E, Halkova T, Kodetova D, Lastuvka P, Betka J, Vlcek P, Reboun M, Katra R, Bendlova B.
    Anticancer Res; 2015 Apr 01; 35(4):2029-36. PubMed ID: 25862857
    [Abstract] [Full Text] [Related]

  • 8. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.
    Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, Cote GJ, Singh RR, Luthra R, Cabanillas ME.
    Thyroid; 2017 Jan 01; 27(1):81-87. PubMed ID: 27785980
    [Abstract] [Full Text] [Related]

  • 9. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
    Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, Taylor BS, Ghossein R, Ganly I, Fagin JA.
    J Clin Invest; 2016 Mar 01; 126(3):1052-66. PubMed ID: 26878173
    [Abstract] [Full Text] [Related]

  • 10. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.
    Kunstman JW, Juhlin CC, Goh G, Brown TC, Stenman A, Healy JM, Rubinstein JC, Choi M, Kiss N, Nelson-Williams C, Mane S, Rimm DL, Prasad ML, Höög A, Zedenius J, Larsson C, Korah R, Lifton RP, Carling T.
    Hum Mol Genet; 2015 Apr 15; 24(8):2318-29. PubMed ID: 25576899
    [Abstract] [Full Text] [Related]

  • 11. Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma.
    Xu B, Ghossein R.
    Endocr Pathol; 2016 Sep 15; 27(3):205-12. PubMed ID: 27372303
    [Abstract] [Full Text] [Related]

  • 12. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
    Teng L, Deng W, Lu J, Zhang J, Ren X, Duan H, Chuai S, Duan F, Gao W, Lu T, Wu H, Liang Z.
    Oncotarget; 2017 Mar 28; 8(13):22023-22033. PubMed ID: 28423545
    [Abstract] [Full Text] [Related]

  • 13. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
    Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI.
    J Clin Endocrinol Metab; 2008 Jan 28; 93(1):278-84. PubMed ID: 17989125
    [Abstract] [Full Text] [Related]

  • 14. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
    Wang HM, Huang YW, Huang JS, Wang CH, Kok VC, Hung CM, Chen HM, Tzen CY.
    Ann Surg Oncol; 2007 Oct 28; 14(10):3011-8. PubMed ID: 17638058
    [Abstract] [Full Text] [Related]

  • 15. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.
    Clin Endocrinol (Oxf); 2008 Apr 28; 68(4):618-34. PubMed ID: 18070147
    [Abstract] [Full Text] [Related]

  • 16. Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets.
    Wu H, Sun Y, Ye H, Yang S, Lee SL, de las Morenas A.
    Pathol Oncol Res; 2015 Jul 28; 21(3):695-701. PubMed ID: 25588542
    [Abstract] [Full Text] [Related]

  • 17. Comprehensive genomic profiling from C-CAT database unveiled over 80% presence of oncogenic drivers in anaplastic thyroid carcinoma including BRAF, RAS family, NF1, and FGFR1.
    Saito Y, Kage H, Kobayashi K, Kamogashira T, Fukuoka O, Yamamura K, Yamashita S, Tanabe M, Oda K, Kondo K.
    Clin Endocrinol (Oxf); 2024 Aug 28; 101(2):170-179. PubMed ID: 38853441
    [Abstract] [Full Text] [Related]

  • 18. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
    Qin Y, Wang JR, Wang Y, Iyer P, Cote GJ, Busaidy NL, Dadu R, Zafereo M, Williams MD, Ferrarotto R, Gunn GB, Wei P, Patel K, Hofmann MC, Cabanillas ME.
    Thyroid; 2021 Aug 28; 31(8):1235-1243. PubMed ID: 33599171
    [Abstract] [Full Text] [Related]

  • 19. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.
    Gauchotte G, Philippe C, Lacomme S, Léotard B, Wissler MP, Allou L, Toussaint B, Klein M, Vignaud JM, Bressenot A.
    Pathology; 2011 Aug 28; 43(5):447-52. PubMed ID: 21716161
    [Abstract] [Full Text] [Related]

  • 20. NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma.
    Tiedje V, Ting S, Herold T, Synoracki S, Latteyer S, Moeller LC, Zwanziger D, Stuschke M, Fuehrer D, Schmid KW.
    Oncotarget; 2017 Jun 27; 8(26):42613-42620. PubMed ID: 28489587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.